KOS 1584

Drug Profile

KOS 1584

Alternative Names: 9,10-Didehydroepothilone D; KOS-1584; R 1645

Latest Information Update: 21 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Kosan Biosciences
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 27 Jun 2008 Kosan Biosciences has been acquired by Bristol-Myers Squibb
  • 14 Apr 2008 Phase-II clinical trials in Non-small cell lung cancer in USA (IV)
  • 30 Oct 2007 KOS 1584 is available for licensing worldwide (http://www.kosan.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top